FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 01:46:09 27/06/2024 pm IST | ||
| 19.53 EUR / 19.79 EUR | +1.92% |
|
| Current month | +11.83% | ||
| 1 month | +10.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 19.29 | +0.68% |
| 25/24/25 | 19.16 | -1.74% |
| 24/24/24 | 19.5 | +2.85% |
| 21/24/21 | 18.96 | -0.42% |
| 20/24/20 | 19.04 | +3.53% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 01:23 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MB7K7M |
| ISIN | DE000MB7K7M8 |
| Date issued | 15/06/2023 |
| Strike | 316.1 $ |
| Maturity | Unlimited |
| Parity | 7.64 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.74 € |
|---|---|
| Lowest since issue | 8.91 € |
| Spread | 0.26 € |
| Spread % | 1.32% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Certificates
- Certificat
